石药巨石生物SYS6010启动Ⅲ期临床适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌_老虎社区_美港股上老虎

石药巨石生物SYS6010启动Ⅲ期临床适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌

新浪财经02-12

药物临床试验登记与信息公示平台数据显示，石药集团巨石生物制药有限公司的SYS6010一项在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌患者中对比SYS6010与研究者选择的单药化疗的有效性和安全性的随机、对照、开放、多中心的Ⅲ期临床研究已启动。临床试验登记号为CTR20260548，首次公示信息日期为2026-02-12。该药物剂型为注射用冻干粉针，用法用量为静脉滴注，按方案规定使用。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2611906562?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-12 18:03","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2611906562","market":"hk","top_or_hot":-1,"title":"石药巨石生物SYS6010启动Ⅲ期临床 适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌","media":"新浪财经","content":"<div>\n<p>药物临床试验登记与信息公示平台数据显示，石药集团巨石生物制药有限公司的SYS6010一项在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌患者中对比SYS6010与研究者选择的单药化疗的有效性和安全性的随机、对照、开放、多中心的Ⅲ期临床研究已启动。临床试验登记号为CTR20260548，首次公示信息日期为2026-02-12。该药物剂型为注射用冻干粉针，用法用量为静脉滴注，按方案规定使用。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212185311a6f3170b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药巨石生物SYS6010启动Ⅲ期临床 适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药巨石生物SYS6010启动Ⅲ期临床 适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-12 18:03 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212185311a6f3170b&s=b><strong>新浪财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>药物临床试验登记与信息公示平台数据显示，石药集团巨石生物制药有限公司的SYS6010一项在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌患者中对比SYS6010与研究者选择的单药化疗的有效性和安全性的随机、对照、开放、多中心的Ⅲ期临床研究已启动。临床试验登记号为CTR20260548，首次公示信息日期为2026-02-12。该药物剂型为注射用冻干粉针，用法用量为静脉滴注，按方案规定使用。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212185311a6f3170b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1993786604.SGD","symbol_name":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212185311a6f3170b&s=b","article_id":"2611906562","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260212185311a6f3170b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611906562","pubTimestamp":1770890580,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"本次试验主要目的为评价SYS6010对比研究者选择的单药化疗在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌参与者中的有效性；次要目的为进一步评价有效性、评价安全性、评价PK特征、评价免疫原性特征及评价EGFR蛋白表达水平与疗效相关性。SYS6010为生物制品，适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌。食管鳞癌是食管癌主要亚型，晚期患者预后差，一线治疗失败后缺乏有效疗法，严重威胁患者生存。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","BK1521":"挪威政府全球养老基金持仓","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","01093":"石药集团","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU0314109678.HKD":"MANULIFE GF DRAGON GROWTH \"AA\" (HKD) INC","IE0008368742.USD":"首域中国增长基金I Acc","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","BK1191":"制药","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","BK1515":"抗疫概念","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1813983027.USD":"MANULIFE GF DRAGON GROWTH \"AA\" (USD) INC"},"translate_title":"CSPC Jushi Biotech SYS6010 initiated phase III clinical indication for locally advanced or metastatic/recurrent esophageal squamous cell carcinoma that has failed at least first-line systemic therapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1.5},"content_text":"药物临床试验登记与信息公示平台数据显示，石药集团巨石生物制药有限公司的SYS6010一项在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌患者中对比SYS6010与研究者选择的单药化疗的有效性和安全性的随机、对照、开放、多中心的Ⅲ期临床研究已启动。临床试验登记号为CTR20260548，首次公示信息日期为2026-02-12。该药物剂型为注射用冻干粉针，用法用量为静脉滴注，按方案规定使用。本次试验主要目的为评价SYS6010对比研究者选择的单药化疗在经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌参与者中的有效性；次要目的为进一步评价有效性、评价安全性、评价PK特征、评价免疫原性特征及评价EGFR蛋白表达水平与疗效相关性。SYS6010为生物制品，适应症为经至少一线系统性治疗失败的局部晚期或转移性/复发食管鳞癌。食管鳞癌是食管癌主要亚型，晚期患者预后差，一线治疗失败后缺乏有效疗法，严重威胁患者生存。本次试验主要终点指标包括BICR基于RECIST 1.1评估的PFS、OS。次要终点指标包括BICR和研究者基于RECIST 1.1评估的ORR、DCR、DoR、CBR；研究者基于RECIST 1.1评估的PFS；TEAE、TRAE的发生类型、频率、严重程度；SYS6010的PK特征；SYS6010的免疫原性；生物标志物EGFR蛋白表达。目前，该试验状态为进行中（尚未招募），目标入组人数436人。声明：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。责任编辑：小浪快报","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}